Report results from Part 2 of the TD-0903 Phase 2 COVID-19 study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 23 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We look forward to reporting data from Part 2 in Q2 2021”
What we found
Evidence strength A What the grades mean
The 10-Q filed August 2021 states top-line results from the Phase 2 Part 2 study of nezulcitinib (formerly TD-0903) were announced in June 2021, before the Q2 2021 deadline.
-
A Theravance Biopharma, Inc. 10-Q filed 2021-08-05
“Phase 2 Part 2 is a randomized, double-blind, parallel-group study evaluating efficacy and safety of one dose (3 mg) of nezulcitinib (selected based on the data from Part 1) as compared with placebo in 200 patients. In June 2021, we announced top-line results” ✓ confirmed on the page
-
A Theravance Biopharma, Inc. 10-Q filed 2021-08-05
“we progressed our preclinical candidate nezulcitinib (formerly known as TD-0903) into the clinic” ✓ confirmed on the page
-
A Theravance Biopharma, Inc. 10-Q filed 2021-11-08
“In June 2021, we announced top-line results from our Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- TD-0903 Phase 2 Part 2 study results
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Theravance Biopharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C583107-024224 · Corrections policy